The Share

The Diamyd Medical share is traded on Nasdaq First North (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North

Nasdaq First North is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399.

Annual Report

  November 9, 2017
  Quarterly Report 3, June 27, 2018

Dear Shareholders and readers

Two weeks ago, Diamyd Medical had another drug enter clinical development phase, when the Swedish Medical Products Agency approved our GABA-based Remygen™ for clinical trials. I would like to clearly highlight the importance of having two drugs — Diamyd® and Remygen™ — in clinical development phase. Both of our clinical development drugs focus on the underlying disease mechanisms in diabetes with the goal of slowing, stopping and ultimately reversing the progression of the disease.

With two drugs in clinical development that complement and strengthen each other, the likelihood increases of making meaningful differences for those who live with diabetes.
Ulf Hannelius, President and CEO

Calendar

 Dates for financial information and other events
Data pager
Data pager
12
October 1, 2018
EASD, Berlin, Germany
54th Annual Meeting of the European Association for the Study of Diabetes (EASD).
October 3, 2018
Financial statement
Financial statement 2017/2018
October 25, 2018
Annual Report
Annual Report 2017/2018
October 25, 2018
IDS, London, UK
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of June 29, 2018

ShareholderA SharesB SharesCapital %Votes %
Essen-Möller, Anders 2 130 186 6 110 867 14.63 36.31
Avanza Pension 6 852 685 12.16 9.08
Lindkvist, Bertil 6 160 000 10.93 8.16
Nordnet Pensionsförsäkring AB 2 230 779 3.96 2.95
Hansen, Patrik 1 300 000 2.31 1.72
Swedbank Försäkring 965 136 1.71 1.28
Arandi Development AB 500 000 0.89 0.66
Konstruktions o Försäljningsaktiebolag 415 000 0.74 0.55
Relbo AB 396 292 0.70 0.52
Försäkrings AB Skandia 362 609 0.64 0.48
Remaining shareholders 28 910 350 51.32 38.29
Total 2 130 186 54 203 718 100.0 100.0